Compare Eni SpA (E) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Neurocrine Biosciences Inc — how do they compare? Eni SpA trades at $56.19 (market cap $79.81B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Eni SpA is far larger — about 5.6× Neurocrine Biosciences Inc's market cap, and Eni SpA pays a 4.39% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Neurocrine Biosciences Inc for 23 Days on average.
| E | NBIX | |
|---|---|---|
Market Cap | $79.81B | $14.36B |
Volume | 365,912 | 1,237,180 |
Sector | Energy | Health |
52-Week High | $57.61 | $185.50 |
52-Week Low | $34.03 | $123.10 |
Typical Hold Time | 53 Days | 23 Days |
Enterprise Value | $104.34B | $14.37B |
Dividend Yield | 4.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $56.02, up 3.82% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows attractive valuation with a P/E of 12.87 and P/S of 0.85. Recent earnings have been mixed, with Q4 2025 beating estimates but Q1 and Q2 2026 missing. Revenue has declined from $132.5B in 2022 to $82.2B in 2025, though net income margin improved to 5.97% in 2026. Positive news includes expansion in Venezuela, Indonesia, and humanoid robotics partnerships.
Outlook is cautiously optimistic given low valuations and strategic initiatives, but risks include volatile energy prices and execution challenges. Analyst consensus is mixed with 34.6% buy ratings. Earnings growth and operational efficiency are key catalysts for upside, while geopolitical and macroeconomic factors pose headwinds.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
